ReviewAnnals of gastroenterological surgery2021
Esophagogastric junction adenocarcinoma shares characteristics with gastric adenocarcinoma: Literature review and retrospective multicenter cohort study.
Review in Annals of gastroenterological surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Outcomes and prognostic factors for patients with Siewert type I/II esophagogastric junction adenocarcinoma following neoadjuvant chemotherapy and surgery: a Japanese cohort study.Surgery today · 2026Article
- Years of Life Lost of Patients With Early Adenocarcinoma of the Esophagogastric Junction Compared to Esophageal or Gastric Adenocarcinoma. A Registry-Based Study.Cancer medicine · 2026Article
- Exosomal lncRNA NORAD drives oxaliplatin resistance in AEG via the miR-433-3p/autophagy axis: a novel mechanism and potential biomarker.Cancer cell international · 2026Article
- The association of survival with adjuvant chemotherapy in patients with ypTNM stage I gastric cancer after neoadjuvant chemotherapy.World journal of surgical oncology · 2026Article
- Efficacy of distal perigastric lymphadenectomy for Siewert type II adenocarcinoma of the esophagogastric junction.Frontiers in surgery · 2025Article
- Machine learning models based on log odds of positive lymph nodes for predicting survival in TFrontiers in oncology · 2025Article
- Presence of Fusobacterium nucleatum in relation to patient survival and an acidic environment in oesophagogastric junction and gastric cancers.British journal of cancer · 2024Article
- Long-Term Outcomes and Risk Factors for Lymph Node Metastasis in Siewert Type II/III Early Gastric Cancer.The Korean journal of helicobacter and upper gastrointestinal research · 2024Article
- Cancer/testis antigen expression and co-expression patterns in gastroesophageal adenocarcinoma.Medical oncology (Northwood, London, England) · 2024Article
- A Rare Case of Ileocecal Lymph Node Recurrence After Surgery in Siewert's Classification Type I Esophagogastric Junction Adenocarcinoma.The American journal of case reports · 2024Article
- Cancer/testis antigen expression and co-expression patterns in Gastroesophageal Adenocarcinoma.Research square · 2024Article
- Usefulness of the preoperative inflammation-based prognostic score and the ratio of visceral fat area to psoas muscle area on predicting survival for surgically resected adenocarcinoma of the esophagogastric junction.Esophagus : official journal of the Japan Esophageal Society · 2024Article
- Immune checkpoint expression and co-expression landscape in gastroesophageal adenocarcinoma.ESMO gastrointestinal oncology · 2024Article
- The development and validation of automated machine learning models for predicting lymph node metastasis in Siewert type II T1 adenocarcinoma of the esophagogastric junction.Frontiers in medicine · 2024Article
- Surgical and Perioperative Treatments for Esophagogastric Junction Cancer.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2024Review
- Neural network-based prognostic predictive tool for gastric cardiac cancer: the worldwide retrospective study.BioData mining · 2023Article
- Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage III gastric or esophagogastric junction adenocarcinoma.Annals of gastroenterological surgery · 2023Article
- Prevention and treatment of a positive proximal margin after gastrectomy for cardia cancer.Updates in surgery · 2023Review
- Prognostic impact of sarcopenia in patients with locally advanced adenocarcinoma of the esophagogastric junction treated with neoadjuvant chemoradiotherapy.Frontiers in nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of esophagogastric junction (EGJ) adenocarcinoma has been gradually increasing in Asia, just like in Western countries a few decades ago. Despite recent advances in next-generation sequencing and multimodal treatments, EGJ adenocarcinoma is still an aggressive malignancy with poor outcomes. Clinically, EGJ adenocarcinoma can be separated into Barrett's adenocarcinoma and cardiac adenocarcinoma, with frequent similarities observed. Barrett's adenocarcinoma is likely to be of gastric origin in terms of its premalignant background, risk factors, and stem cell regulators. Recent comprehensive genomic analyses suggest that immunotherapy may be essential for high-level microsatellite instability (MSI-H)- and Epstein-Barr virus (EBV)-associated subtypes, and against the immunosuppressive phenotype in genomically stable (GS) subtypes, in the treatment of EGJ and gastric adenocarcinoma. Although the chromosomal instability (CIN) subtype dominates EGJ adenocarcinoma, there is still a need to investigate the other molecular subtypes and their targets. Because of the distinctive characteristics of tumor location of EGJ adenocarcinoma, we also described the results of a multicenter cohort study of EGJ adenocarcinoma, comparing Siewert type I (distal esophagus), II (cardia of the stomach), and III (subcardia) tumors. We show that type I tumors were frequently accompanied by Barrett's esophagus (78%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.